HRP20170868T1 - Liječenje alergije na kikiriki - Google Patents
Liječenje alergije na kikiriki Download PDFInfo
- Publication number
- HRP20170868T1 HRP20170868T1 HRP20170868TT HRP20170868T HRP20170868T1 HR P20170868 T1 HRP20170868 T1 HR P20170868T1 HR P20170868T T HRP20170868T T HR P20170868TT HR P20170868 T HRP20170868 T HR P20170868T HR P20170868 T1 HRP20170868 T1 HR P20170868T1
- Authority
- HR
- Croatia
- Prior art keywords
- dose
- peanut
- therapeutic composition
- peanut protein
- use according
- Prior art date
Links
- 201000010853 peanut allergy Diseases 0.000 title claims 6
- 206010016946 Food allergy Diseases 0.000 title claims 5
- 208000008267 Peanut Hypersensitivity Diseases 0.000 title claims 5
- 239000000203 mixture Substances 0.000 claims 12
- 235000017060 Arachis glabrata Nutrition 0.000 claims 11
- 241001553178 Arachis glabrata Species 0.000 claims 11
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 11
- 235000018262 Arachis monticola Nutrition 0.000 claims 11
- 235000020232 peanut Nutrition 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 4
- 235000013312 flour Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008267 milk Substances 0.000 claims 2
- 210000004080 milk Anatomy 0.000 claims 2
- 235000013336 milk Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 208000025864 peanut allergic reaction Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Terapeutski sastav koji sadrži protein kikirikija, naznačen time, da se upotrebljava u postupku liječenja pojedinca koji ima alergiju na kikiriki, pri čemu to obuhvaća sljedeće korake:
(1) pripremanje pojedinca koji ima alergiju na kikiriki;
2. oralno davanje pacijentu dnevne doze proteina kikirikija, pri čemu se dnevna oralna doza povećava u vremenskim intervalima od najmanje dva tjedna u serijskim povećanjima doze, počevši od inicijalne doze od 2 mg do maksimalne doze od 800 mg ili manje, gdje serijska povećanja doze obuhvaćaju 2 mg, 5 mg, 12,5 mg, 25 mg, 50 mg, 100 mg i 200 mg;
3. davanje dnevne oralne doze u maksimalnoj dozi proteina kikirikija za vrijeme od najmanje godinu dana nakon koraka (2).
2. Terapeutski sastav za uporabu prema zahtjevu 1, naznačen time, da se serijska povećanja doze sastoje od 2 mg, 5 mg, 12,5 mg, 25 mg, 50 mg, 100 mg i 200 mg.
3. Terapeutski sastav za uporabu prema bilo kojem od zahtjeva 1 do 2, naznačen time, da se protein kikirikija primjenjuje u obliku brašna od kikirikija.
4. Terapeutski sastav za uporabu prema zahtjevu 3, naznačen time, da se brašno od kikirikija miješa s nosačem za primjenu.
5. Terapeutski sastav za uporabu prema zahtjevu 4, naznačen time, da nosač je mlijeko ili zamjenski mliječni proizvod.
6. Terapeutski sastav za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da je terapeutski sastav u obliku jedinične doze i obuhvaća dozu odabranu od 2 mg, 5 mg, 12,5 mg, 25 mg, 50 mg, 100 mg i 200 mg.
7. Skupina kompleta terapeutskih sastava, naznačena time, da svaki komplet u skupini obuhvaća višestruke odvojene formulacije jedinične doze proteina kikirikija i svaka formulacija jedinične doze u kompletu, obuhvaća identičnu količinu proteina kikirikija, dok pritom skupina uključuje komplete s formulacijama jedinične doze, koje obuhvaćaju 2 mg, 5 mg, 12,5 mg, 25 mg, 50 mg, 100 mg i 200 mg proteina kikirikija, gdje svaki komplet u skupini obuhvaća četrnaest formulacija jedinične doze.
8. Skupina kompleta prema zahtjevu 7, naznačena time, da se upotrebljava kao lijek.
9. Skupina kompleta prema zahtjevu 7, naznačena time, da se upotrebljava u postupku liječenja alergije na kikiriki.
10. Skupina kompleta za uporabu prema zahtjevu 9, naznačena time, da postupak liječenja alergije na kikiriki obuhvaća sljedeće korake:
(1) pripremanje pojedinca koji ima alergiju na kikiriki;
(2) oralno davanje pacijentu dnevne doze proteina kikirikija, pri čemu se dnevna oralna doza povećava u vremenskim intervalima od najmanje dva tjedna u serijskim povećanjima doze, počevši od inicijalne doze od 2 mg do maksimalne doze od 800 mg ili manje, gdje se serijska povećanja doze sastoje od 2 mg, 5 mg, 12,5 mg, 25 mg, 50 mg, 100 mg i 200 mg; i
(3) davanje dnevne oralne doze u maksimalnoj dozi proteina kikirikija za vrijeme od najmanje godinu dana nakon koraka (2).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1104537.4A GB201104537D0 (en) | 2011-03-17 | 2011-03-17 | Treatment for peanut allergy |
| EP12712344.6A EP2686013B1 (en) | 2011-03-17 | 2012-03-16 | Treatment for peanut allergy |
| PCT/GB2012/050584 WO2012123759A1 (en) | 2011-03-17 | 2012-03-16 | Treatment for peanut allergy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170868T1 true HRP20170868T1 (hr) | 2017-08-25 |
Family
ID=44012746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170868TT HRP20170868T1 (hr) | 2011-03-17 | 2017-06-07 | Liječenje alergije na kikiriki |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9481716B2 (hr) |
| EP (1) | EP2686013B1 (hr) |
| JP (1) | JP2014509606A (hr) |
| CN (1) | CN103596589A (hr) |
| AU (1) | AU2012228033B2 (hr) |
| CA (1) | CA2867529C (hr) |
| CY (1) | CY1119074T1 (hr) |
| DK (1) | DK2686013T3 (hr) |
| ES (1) | ES2633319T3 (hr) |
| GB (1) | GB201104537D0 (hr) |
| HR (1) | HRP20170868T1 (hr) |
| HU (1) | HUE035385T2 (hr) |
| LT (1) | LT2686013T (hr) |
| PL (1) | PL2686013T3 (hr) |
| PT (1) | PT2686013T (hr) |
| RS (1) | RS56043B1 (hr) |
| SG (2) | SG193518A1 (hr) |
| SI (1) | SI2686013T1 (hr) |
| WO (1) | WO2012123759A1 (hr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11096994B2 (en) * | 2012-10-30 | 2021-08-24 | Aravax Pty Ltd | Immunotherapeutic molecules and uses thereof |
| DK3482771T3 (da) * | 2013-03-14 | 2023-03-20 | Nestle Sa | Fremstilling af jordnøddeformuleringer til oral desensibilisering |
| WO2014159609A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Peanut formulations and uses thereof |
| KR102212253B1 (ko) * | 2013-03-15 | 2021-02-04 | 세멘티스 리미티드 | 면역 조절 |
| US20150343075A1 (en) * | 2014-06-02 | 2015-12-03 | Aimmune Therapeutics | Placebo formulations and uses thereof |
| EP4275760A3 (en) | 2014-08-25 | 2024-02-07 | Société des Produits Nestlé S.A. | Egg protein formulations and methods of manufacture thereof |
| US10166286B2 (en) | 2015-02-20 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10149904B2 (en) | 2015-02-20 | 2018-12-11 | The Board Of Trusteees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10143742B2 (en) | 2015-02-20 | 2018-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10064936B2 (en) * | 2015-02-20 | 2018-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US11452774B2 (en) | 2015-02-20 | 2022-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| WO2016138030A2 (en) * | 2015-02-23 | 2016-09-01 | Antera Therapeutics Inc. | Compositions and methods for tolerizing the immune system to allergens |
| US20170021010A1 (en) * | 2015-07-21 | 2017-01-26 | David Phillip ERSTEIN | Allergy preventing dosage controlled food packets |
| US10856567B2 (en) * | 2016-07-22 | 2020-12-08 | Kari Brown | Baby food products containing allergenic proteins and methods of delivering same |
| CA3069967A1 (en) | 2017-07-18 | 2019-01-24 | Before Brands, Inc. | Methods for making mixed allergen compositions |
| US10603376B2 (en) | 2017-08-30 | 2020-03-31 | Roberto Garcia-Ibanez | Immunotherapy for the treatment of allergic disease |
| CA3080601A1 (en) | 2017-11-02 | 2019-05-09 | Aimmune Therapeutics, Inc. | Methods of oral immunotherapy |
| GB201718342D0 (en) | 2017-11-06 | 2017-12-20 | Cambridge Allergy Ltd | Allergenic protein formulations for immunotherapy |
| EP3720432A4 (en) * | 2017-12-06 | 2021-08-25 | Prollergy Corporation | COMPOSITION AND METHOD FOR MITIGATING AN ALLERGIC REACTION |
| US20200345033A1 (en) * | 2018-01-16 | 2020-11-05 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment and prevention of seed allergies |
| JP7526723B2 (ja) * | 2018-05-22 | 2024-08-01 | アラージェニス エルエルシー | ピーナッツアレルギーを検出するためのペプチド及び方法 |
| US11406563B2 (en) | 2018-07-27 | 2022-08-09 | Société des Produits Nestlé S.A. | Oral immunotherapy unit dose dispensing systems and methods |
| EP3836801A4 (en) * | 2018-08-16 | 2022-05-18 | Société des Produits Nestlé S.A. | ORAL PEANUT DESENSITIZATION IMMUNOTHERAPY WITH MAINTENANCE DOSE |
| WO2020100024A1 (en) * | 2018-11-12 | 2020-05-22 | Murdoch Childrens Research Institute | Method and system |
| US20200230206A1 (en) * | 2018-12-20 | 2020-07-23 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy dosing schedule for missed doses |
| WO2020154476A1 (en) | 2019-01-23 | 2020-07-30 | Before Brands, Inc. | Methods for making mixed allergen compositions |
| WO2020198024A1 (en) * | 2019-03-22 | 2020-10-01 | Aimmune Therapeutics, Inc. | Systemic allergic response risk assessment in peanut oral immunotherapy |
| US11229673B2 (en) | 2019-05-10 | 2022-01-25 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
| WO2020237181A1 (en) * | 2019-05-23 | 2020-11-26 | Aimmune Therapeutics, Inc. | Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance |
| AU2020412960A1 (en) * | 2019-12-23 | 2022-06-16 | Prota Therapeutics Pty Ltd | Allergy treatment |
| KR20220119076A (ko) * | 2019-12-23 | 2022-08-26 | 프로타 테라퓨틱스 피티와이 엘티디 | 약학적 조성물 |
| WO2023200316A1 (ko) * | 2022-04-15 | 2023-10-19 | 사회복지법인 삼성생명공익재단 | 경구면역요법을 이용한 식품알레르기 치료서비스 제공방법, 이를 구현하기 위한 기록매체에 저장된 컴퓨터 프로그램 및 시스템 |
| NL2033338B1 (en) | 2022-10-17 | 2024-05-03 | Vini Mini B V | Prevention of tree nut and seed allergy in humans |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05005528A (es) * | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
-
2011
- 2011-03-17 GB GBGB1104537.4A patent/GB201104537D0/en not_active Ceased
-
2012
- 2012-03-16 HU HUE12712344A patent/HUE035385T2/en unknown
- 2012-03-16 SG SG2013070115A patent/SG193518A1/en unknown
- 2012-03-16 CN CN201280022718.XA patent/CN103596589A/zh active Pending
- 2012-03-16 LT LTEP12712344.6T patent/LT2686013T/lt unknown
- 2012-03-16 AU AU2012228033A patent/AU2012228033B2/en active Active
- 2012-03-16 ES ES12712344.6T patent/ES2633319T3/es active Active
- 2012-03-16 PL PL12712344T patent/PL2686013T3/pl unknown
- 2012-03-16 WO PCT/GB2012/050584 patent/WO2012123759A1/en active Application Filing
- 2012-03-16 JP JP2013558515A patent/JP2014509606A/ja active Pending
- 2012-03-16 CA CA2867529A patent/CA2867529C/en active Active
- 2012-03-16 SG SG10201602013SA patent/SG10201602013SA/en unknown
- 2012-03-16 SI SI201231014T patent/SI2686013T1/sl unknown
- 2012-03-16 PT PT127123446T patent/PT2686013T/pt unknown
- 2012-03-16 US US14/005,789 patent/US9481716B2/en active Active
- 2012-03-16 EP EP12712344.6A patent/EP2686013B1/en active Active
- 2012-03-16 DK DK12712344.6T patent/DK2686013T3/en active
- 2012-03-16 RS RS20170551A patent/RS56043B1/sr unknown
-
2017
- 2017-06-07 HR HRP20170868TT patent/HRP20170868T1/hr unknown
- 2017-07-12 CY CY20171100743T patent/CY1119074T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2686013T3 (en) | 2017-07-10 |
| EP2686013A1 (en) | 2014-01-22 |
| HUE035385T2 (en) | 2018-05-02 |
| SG193518A1 (en) | 2013-10-30 |
| PL2686013T3 (pl) | 2017-10-31 |
| CA2867529C (en) | 2022-08-23 |
| CY1119074T1 (el) | 2018-01-10 |
| US9481716B2 (en) | 2016-11-01 |
| LT2686013T (lt) | 2017-07-10 |
| AU2012228033A1 (en) | 2013-10-31 |
| CA2867529A1 (en) | 2012-09-20 |
| US20140093541A1 (en) | 2014-04-03 |
| PT2686013T (pt) | 2017-07-18 |
| GB201104537D0 (en) | 2011-05-04 |
| SG10201602013SA (en) | 2016-04-28 |
| ES2633319T3 (es) | 2017-09-20 |
| CN103596589A (zh) | 2014-02-19 |
| EP2686013B1 (en) | 2017-05-03 |
| RS56043B1 (sr) | 2017-09-29 |
| WO2012123759A1 (en) | 2012-09-20 |
| JP2014509606A (ja) | 2014-04-21 |
| AU2012228033B2 (en) | 2016-09-15 |
| SI2686013T1 (sl) | 2017-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170868T1 (hr) | Liječenje alergije na kikiriki | |
| Kadriu et al. | Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments | |
| US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
| NI201100194A (es) | Derivados de tieno [2, 3 - b] piridina como inhibidores de la replicación viral | |
| RU2010105122A (ru) | Композиции для ухода за полостью рта, продукты и способы применения | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| SI2501234T1 (en) | METHODS AND INGREDIENTS FOR TREATMENT OF SYMPTOMS RELATED TO POST-TRAUMATIC STRESS EMISSIONS WITH THE USE OF CYCLOBENZAPRINE | |
| HRP20200142T1 (hr) | Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina | |
| JP2012236834A5 (hr) | ||
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| JP2016505050A5 (hr) | ||
| AR065816A1 (es) | Regimen anticonceptivo oral | |
| ES2656913T3 (es) | Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes | |
| AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
| RU2014146562A (ru) | Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий | |
| EA200501621A1 (ru) | Антигриппозное средство | |
| JP2017530142A5 (hr) | ||
| ES2587932T3 (es) | Composiciones para su uso en el alivio de los síntomas asociados con el síndrome premenstrual y el trastorno disfórico premenstrual | |
| CN106511447A (zh) | 一种细胞障碍修复营养补充方法及其药物配方 | |
| JP2013542262A5 (hr) | ||
| RU2532399C2 (ru) | Способ лечения пародонтита | |
| EA201692107A1 (ru) | Схема лечения тиакумициновым соединением | |
| CN102784381A (zh) | 一种治疗白内障的临床科研配方 | |
| TWI599371B (zh) | 醫藥組合物用於製備治療檳榔使用失調之藥物上的用途 | |
| CN104623492A (zh) | 治疗慢性胃炎的中药配方 |